Clinical Development: Oncology
CT01681’s ability to safely modulate the cytokine response makes it an ideal solution to address CAR T-Cell Therapy and Bispecific Antibody related CRS in oncology
Download White Paper
Chairman, UPMC Hillman Cancer Center
Dr. Marks on CRS in
CAR T-Cell Patients
“As someone who has dedicated my life to cancer treatment, patient advocacy and innovation, I’m highly motivated to solve the CRS problem associated with CAR T-Cell Therapy. CTO1681 could not only treat, but perhaps prevent, CRS altogether. Reducing this life-threatening side effect will allow us to treat and cure more patients with CAR T-Cell Therapy.”
Addressing Unmet Needs in Oncology
CTO1681 Treats CRS Triggered by
CAR T-Cell Therapy and Bispecific Antibody Therapy
CTO1681 reduces the cytokines generated during Cytokine Release Syndrome CAR T-Cell Therapy while enabling the body to maintain appropriate cytokine levels. Reducing the rates and severity of toxicity allows for the treatment of more patients, treatment in the outpatient setting, and the decrease of treatment-related morbidity.
In addition to CAR T-Cell Therapy, Bispecific Antibody Therapies are an emerging therapeutic area in immune-oncology that has a significant incidence of CRS. CTO1681 reduces cytokines generated during CRS induced by Bispecific Antibodies without causing systemic off-target effects or increasing the risk of neurotoxicity like current CRS treatments.
Using CTO1681 in Conjunction with
CAR T-Cell Therapy
CTO1681’s ability to modulate the cytokine response makes it a promising candidate to mitigate a common side effect of CAR T-cell therapy in oncology.
Clinical Trial Timeline
- Phase 1 Clinical Trial Completed – 3Q2021
- Preclinical Studies Completed – 1Q2023
- Phase 1b/2a Clinical Trial Commenced – 2Q2023